Pediatric Respirology and Critical Care Medicine

REVIEW ARTICLE
Year
: 2020  |  Volume : 4  |  Issue : 2  |  Page : 25--27

Treatment of mild to moderate COVID-19 in children


Sushil Kumar Kabra 
 Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, India

Correspondence Address:
Sushil Kumar Kabra
Department of Pediatrics, All India Institute of Medical Sciences, New Delhi - 110 029
India

Children as such have less infection and less severe covid 19 illness. Majority will be asymptomatic or mildly symptomatic. Symptoms are nonspecific and suspect in children presenting with influenza-like illness (ILI) or children presenting with respiratory difficulty. Children with definite contact with COVID-positive patients or those who had severe illness (irrespective of COVID status) in the past 2 weeks should be subjected to test. The rest of the children may be tested if any of the following are present: 1. The presence of high-risk factor in child such as immunocompromised condition (long-term steroids, cancer chemotherapy, biological agents, and primary or secondary immune deficiency) or chronic illnesses including chronic respiratory illnesses 2. Any person in family who is at risk of developing serious illness (elderly, immunocompromised, diabetic, hypertensive, etc.,). Majority of mild to moderate illness can be managed at home with symptomatic treatment ensuring monitoring for worsening of symptoms. There is no proven benefit of antibiotics, antiviral agents, steroids, hydroxychloroquine or other anti-inflammatory agents.


How to cite this article:
Kabra SK. Treatment of mild to moderate COVID-19 in children.Pediatr Respirol Crit Care Med 2020;4:25-27


How to cite this URL:
Kabra SK. Treatment of mild to moderate COVID-19 in children. Pediatr Respirol Crit Care Med [serial online] 2020 [cited 2021 Apr 16 ];4:25-27
Available from: https://www.prccm.org/article.asp?issn=2543-0343;year=2020;volume=4;issue=2;spage=25;epage=27;aulast=Kabra;type=0